Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

As part of the continuing effort to develop an effective HIV vaccine, we generated a poxviral vaccine vector (previously described) designed to improve on the results of the RV144 phase III clinical trial. The construct, NYVAC-KC, is a replication-competent, attenuated recombinant of the vaccinia vi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Virol
Auteurs principaux: Kibler, Karen V., Asbach, Benedikt, Perdiguero, Beatriz, García-Arriaza, Juan, Yates, Nicole L., Parks, Robert, Stanfield-Oakley, Sherry, Ferrari, Guido, Montefiori, David C., Tomaras, Georgia D., Roederer, Mario, Foulds, Kathryn E., Forthal, Donald N., Seaman, Michael S., Self, Steve, Gottardo, Raphael, Phogat, Sanjay, Tartaglia, James, Barnett, Susan, Cristillo, Anthony D., Weiss, Deborah, Galmin, Lindsey, Ding, Song, Heeney, Jonathan L., Esteban, Mariano, Wagner, Ralf, Pantaleo, Giuseppe, Jacobs, Bertram L.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2019
Sujets:
Vaccines and Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6340019/
https://ncbi.nlm.nih.gov/pubmed/30429340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01513-18
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires